CANVAS Trial: Oral Blood Thinner as Effective as Injectable Type in Preventing Blood Clots in Adults with Cancer
About Us
- 2023 Annual Meeting
- About PCORI
- The PCORI Strategic Plan
- Governance
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
-
Provide Input
-
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
-
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
-
Past Opportunities to Provide Input
- Leadership
Image
Adults with cancer who took a newer oral blood thinner to prevent recurrent venous thromboembolism (VTE), or blood clots, fared just as well as those who took an older injectable blood thinner, according to PCORI-funded study results published in JAMA this month.
The CANVAS Trial—led by Deborah Schrag, MD, MPH, at the Alliance for Clinical Trials in Oncology Foundation—compared the effectiveness of direct oral anticoagulants (DOACs) with injectable low-molecular-weight heparin (LMHW) among 638 adults with cancer at 67 sites.
Following a six-month treatment period, the study team found that DOAC treatment was noninferior to LMHW treatment for preventing recurrent VTE. In addition, there were no significant differences between the two groups in bleeding, mortality, serious adverse events, quality of life, or burden and benefits of medication.
Posted: June 12, 2023
Tags
Recent Posts
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
